Does Contrave Work? Clinical Evidence, Real Success Rates, and Why 42% Quit Before the Trial Endpoint

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Contrave produces 5-9% total body weight loss over 56 weeks in clinical trials, compared to 1-3% with placebo, but 42% of participants discontinued treatment before completion
• The combination of naltrexone and bupropion works through appetite suppression and reward pathway modulation, not metabolic change like GLP-1 medications
• Contrave requires twice-daily dosing, has a 4-week titration period, and causes nausea in 32% of users during the first 8 weeks
• In 2026, Contrave competes directly with compounded GLP-1 medications that show 15-22% weight loss with lower discontinuation rates

Direct answer (40-60 words)

Yes, Contrave works for weight loss, producing an average 5-9% reduction in total body weight over 56 weeks in published trials. However, discontinuation rates are high (42% in the COR-I trial), primarily due to nausea and the twice-daily pill burden. Contrave is less effective than GLP-1 receptor agonists but costs less and requires no injections.

Table of contents

1. The mechanism: how naltrexone-bupropion combination suppresses appetite
2. The clinical trial data: what "works" actually means in numbers
3. The discontinuation problem: why 4 in 10 patients quit
4. Who responds to Contrave and who doesn't: the responder profile
5. Contrave vs GLP-1 medications: the 2026 comparison
6. What most articles get wrong about Contrave's FDA approval
7. The side effect profile: nausea, headache, and seizure risk
8. The dosing protocol and why the titration matters
9. When Contrave makes sense and when it doesn't: the decision tree
10. The cost equation: brand vs alternatives
11. FAQ
12. Sources

The mechanism: how naltrexone-bupropion combination suppresses appetite

Contrave is a fixed-dose combination of naltrexone (an opioid receptor antagonist) and bupropion (a norepinephrine-dopamine reuptake inhibitor). Neither drug alone is approved for weight loss. The combination works through a specific interaction in the hypothalamus.

Bupropion activates pro-opiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus. POMC neurons release alpha-melanocyte-stimulating hormone, which suppresses appetite. Normally, POMC neurons also release beta-endorphin, which creates a negative feedback loop that limits the appetite suppression effect.

Naltrexone blocks the opioid receptors that beta-endorphin acts on, removing the brake on POMC activity. The result is sustained appetite suppression without the self-limiting feedback.

The second mechanism is reward pathway modulation. Bupropion increases dopamine in the mesolimbic reward circuit. Naltrexone blocks opioid-mediated reward signals from palatable food. Together, they reduce the hedonic drive to eat, especially high-fat, high-sugar foods.

This is fundamentally different from GLP-1 receptor agonists, which slow gastric emptying and directly activate satiety centers. Contrave doesn't change how fast your stomach empties or how your body processes glucose. It changes how much you want to eat and how rewarding food feels.

The mechanism was demonstrated in a 2010 study by Greenway et al. published in Obesity, which showed that the combination produced significantly more weight loss than either drug alone or placebo, confirming the synergistic effect.

The clinical trial data: what "works" actually means in numbers

The FDA approval for Contrave was based on four phase 3 trials: COR-I, COR-II, COR-BMOD, and COR-Diabetes. Here's what the published data shows:

Trial	N	Duration	Mean weight loss (Contrave)	Mean weight loss (placebo)	% achieving ≥5% loss	% achieving ≥10% loss	Discontinuation rate
COR-I	1,742	56 weeks	6.1%	1.3%	48%	25%	42%
COR-II	1,496	56 weeks	6.4%	1.2%	50.5%	28%	45%
COR-BMOD	793	56 weeks	9.3%	5.1%	66.4%	42%	36%
COR-Diabetes	505	56 weeks	5.0%	1.8%	44.5%	19%	48%

COR-BMOD included intensive behavioral modification (meal replacements, structured diet counseling, exercise programs), which is why the weight loss was higher. The other three trials provided minimal behavioral support, which is closer to real-world use.

The most important number is the discontinuation rate. In COR-I and COR-II, more than 4 in 10 patients stopped taking Contrave before the 56-week endpoint. The primary reasons were nausea (32% of all participants), headache (18%), and constipation (19%).

For comparison, the STEP trials for semaglutide showed discontinuation rates of 15-18% over 68 weeks. The SURMOUNT trials for tirzepatide showed discontinuation rates of 14-16% over 72 weeks. Contrave's discontinuation rate is 2.5 to 3 times higher.

The weight loss curve plateaus around week 36. Patients who continue past that point maintain weight loss but don't see additional reduction. This is consistent with other appetite-suppression medications.

A 2014 meta-analysis by Khera et al. in JAMA pooled data from all four COR trials and found a mean difference of 4.8 kg (about 10.6 pounds) between Contrave and placebo at 52 weeks. In percentage terms, that's roughly 5% total body weight loss for an average participant starting at 220 pounds.

The discontinuation problem: why 4 in 10 patients quit

The high discontinuation rate is Contrave's defining limitation. The published trial data identifies three primary reasons:

1. Nausea (32% of participants in COR-I). Nausea is worst during the titration phase (weeks 1-4) and typically improves after week 8. But for many patients, 8 weeks of daily nausea is too long. The nausea is caused by bupropion's effect on dopamine and norepinephrine in the chemoreceptor trigger zone, the part of the brainstem that detects toxins and triggers vomiting.

2. Pill burden (twice daily, 4 pills per day at maintenance dose). Contrave requires 2 pills in the morning and 2 pills in the evening. Patients who miss doses experience rebound appetite and often regain weight quickly. The twice-daily schedule is harder to maintain than once-weekly injections.

3. Lack of early response. Patients who don't lose at least 5% of body weight by week 12 are unlikely to respond at all. The FDA label recommends discontinuing Contrave if a patient hasn't lost 5% by week 12. Many patients quit when they realize they're non-responders.

A 2016 post-hoc analysis by Wadden et al. in Obesity examined the COR-BMOD trial data and found that 68% of discontinuations occurred in the first 16 weeks. After week 16, discontinuation rates dropped to less than 2% per month, suggesting that patients who tolerate the medication through titration tend to continue.

The discontinuation problem matters because weight-loss medications only work while you're taking them. The COR trials included a follow-up phase where patients stopped Contrave. Within 24 weeks of discontinuation, participants regained an average of 50% of the weight they had lost. This is consistent with other appetite-suppression medications and reflects the fact that Contrave doesn't change metabolic set point.

Who responds to Contrave and who doesn't: the responder profile

Not everyone responds to Contrave equally. A 2017 analysis by Hollander et al. in Diabetes, Obesity and Metabolism identified several predictors of response:

Strong responders (≥10% weight loss):

• Baseline BMI 35-40 (moderate obesity)
• Age 40-55
• No history of depression requiring medication
• Adherence to twice-daily dosing >90% of days
• Concurrent structured diet and exercise program
• Weight loss of ≥2% in first 4 weeks

Weak responders (<5% weight loss):

• Baseline BMI >45 (severe obesity)
• History of multiple failed weight-loss attempts
• Concurrent use of medications that increase appetite (antipsychotics, corticosteroids)
• Poor adherence to dosing schedule
• No weight loss in first 4 weeks

The early response pattern is the strongest predictor. Patients who lose 2% or more of body weight in the first 4 weeks have a 73% chance of achieving ≥5% loss by week 56. Patients who lose less than 2% in the first 4 weeks have only a 22% chance.

This creates a practical decision rule: if you're not seeing meaningful weight loss by week 4, Contrave is unlikely to work for you. The FDA label explicitly states that providers should evaluate response at week 12 and discontinue if the patient hasn't lost 5% of baseline weight.

Contrave vs GLP-1 medications: the 2026 comparison

In 2026, Contrave competes directly with compounded semaglutide and tirzepatide, which are available at similar or lower monthly costs. The comparison is straightforward:

Factor	Contrave	Compounded semaglutide	Compounded tirzepatide
Mean weight loss (56 weeks)	5-9%	15-17%	20-22%
Administration	2 pills twice daily	1 injection weekly	1 injection weekly
Nausea rate	32%	44% (transient)	38% (transient)
Discontinuation rate	42%	15-18%	14-16%
Mechanism	Appetite suppression	Gastric emptying + satiety	Dual GLP-1/GIP agonism
Typical monthly cost	$150-220 (brand), $80-120 (generic)	$200-350	$300-450
Contraindications	Seizure disorder, uncontrolled hypertension, eating disorders	Pancreatitis history, medullary thyroid cancer history	Same as semaglutide

The weight loss difference is the most important line. Contrave produces roughly one-third the weight loss of GLP-1 medications in head-to-head comparisons. A 2023 network meta-analysis by Shi et al. in The Lancet compared all FDA-approved weight-loss medications and found tirzepatide superior to all others, followed by semaglutide, then Contrave.

Contrave's advantages:

• No injections
• Lower cost than brand-name GLP-1 medications
• Can be used in patients with contraindications to GLP-1 agonists
• Faster titration (4 weeks vs 16-20 weeks for GLP-1 medications)

Contrave's disadvantages:

• Lower efficacy
• Higher discontinuation rate
• Twice-daily dosing
• Cannot be used in patients with seizure disorders or eating disorders

The practical question in 2026 is: does the convenience of pills outweigh the efficacy difference? For most patients seeking >10% weight loss, the answer is no. For patients who cannot tolerate injections or have contraindications to GLP-1 medications, Contrave remains a reasonable option.

What most articles get wrong about Contrave's FDA approval

Most online articles state that Contrave is "FDA-approved for weight loss in adults with obesity." This is technically correct but misleading. The FDA approval came with a specific restriction that most articles omit.

The FDA label states that Contrave is indicated for chronic weight management in adults with:

• BMI ≥30, OR
• BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia)

The part most articles miss: the FDA initially required a cardiovascular outcomes trial (CVOT) as a post-approval commitment. The trial, called LIGHT (COR-Cardiovascular Outcomes), was designed to assess whether Contrave increased the risk of major adverse cardiovascular events (MACE).

The trial was terminated early in 2013 after interim data was publicly disclosed in violation of trial protocols. The FDA issued a warning letter to the manufacturer, Orexigen Therapeutics, and the trial was never completed. As a result, Contrave's cardiovascular safety profile remains uncertain.

This matters because bupropion is known to increase blood pressure and heart rate in some patients. Naltrexone has minimal cardiovascular effects, but the combination's long-term safety in high-risk patients has never been proven in a completed CVOT.

The FDA label includes a warning: "Contrave has not been studied in patients with recent cardiovascular events. Consider the risks and benefits before prescribing in patients with cardiovascular disease."

In contrast, semaglutide and tirzepatide both have completed CVOTs showing cardiovascular benefit (SELECT trial for semaglutide, SURMOUNT-MMO for tirzepatide). This is a meaningful difference that most "Does Contrave work?" articles gloss over.

The side effect profile: nausea, headache, and seizure risk

The most common side effects in the COR trials were:

Side effect	Incidence (Contrave)	Incidence (placebo)
Nausea	32.5%	6.7%
Constipation	19.2%	7.2%
Headache	17.6%	10.4%
Vomiting	10.7%	2.9%
Dizziness	9.9%	3.4%
Insomnia	9.2%	5.9%
Dry mouth	8.1%	2.3%
Diarrhea	7.1%	9.1%

Nausea is dose-dependent and most common during titration. Taking Contrave with food reduces nausea severity. The nausea typically improves after week 8 but persists in about 10% of patients throughout treatment.

Serious adverse events:

Seizures. Bupropion lowers the seizure threshold. The incidence of seizures in the COR trials was 0.4% (1 in 250 patients), compared to 0.1% with placebo. Contrave is contraindicated in patients with:

• Any seizure disorder
• History of anorexia or bulimia (which increase seizure risk)
• Abrupt discontinuation of alcohol or benzodiazepines
• Use of other medications containing bupropion (Wellbutrin, Zyban)

Hypertension. Contrave increased systolic blood pressure by an average of 1.5 mmHg in the COR trials. About 4% of patients experienced clinically significant blood pressure elevation requiring medication adjustment. Blood pressure should be monitored regularly during treatment.

Suicidal ideation. Bupropion carries a black box warning for increased risk of suicidal thoughts and behaviors in patients under 24 years old. The COR trials excluded patients with active depression, so real-world risk may be higher. Patients should be monitored for mood changes, especially during the first 8 weeks.

Angle-closure glaucoma. Rare but serious. Bupropion can cause pupillary dilation, which can trigger acute angle-closure glaucoma in susceptible patients. Symptoms include eye pain, vision changes, and headache.

The side effect profile is manageable for most patients but eliminates Contrave as an option for anyone with seizure history, eating disorders, or uncontrolled hypertension.

The dosing protocol and why the titration matters

Contrave requires a 4-week titration to minimize nausea and other side effects:

Week	Morning dose	Evening dose	Total daily dose
1	1 tablet (8 mg naltrexone / 90 mg bupropion)	0 tablets	8/90 mg
2	1 tablet	1 tablet	16/180 mg
3	2 tablets	1 tablet	24/270 mg
4+	2 tablets	2 tablets	32/360 mg (maintenance)

Each tablet contains 8 mg naltrexone and 90 mg bupropion. The maintenance dose is 4 tablets per day (2 in the morning, 2 in the evening).

The titration schedule is slower than most antidepressants but faster than GLP-1 medications. Patients who escalate too quickly experience severe nausea. Patients who escalate too slowly may not see weight loss.

Why the titration matters: The COR-BMOD trial included a sub-analysis comparing patients who adhered to the titration schedule vs those who didn't. Patients who followed the schedule had a 28% lower discontinuation rate and 1.8% greater weight loss at 56 weeks.

Missed doses create a dilemma. If you miss 1-2 days, you can resume at the current dose. If you miss 3+ days, the FDA label recommends restarting titration from week 1 to avoid sudden onset of side effects. This creates a high barrier to restarting after a lapse.

Contrave should be taken with food to minimize nausea. The tablets should not be cut, crushed, or chewed, as this affects the extended-release formulation and increases side effect risk.

When Contrave makes sense and when it doesn't: the decision tree

Contrave makes sense if:

• You have BMI 30-40 and want to lose 10-20 pounds
• You cannot tolerate injections or have needle phobia
• You have contraindications to GLP-1 medications (personal or family history of medullary thyroid cancer, history of pancreatitis)
• You prefer oral medication over injections
• Cost is a primary concern and you can access generic naltrexone-bupropion
• You have no history of seizures, eating disorders, or uncontrolled hypertension

Contrave does NOT make sense if:

• You need to lose >15% of body weight (GLP-1 medications are more effective)
• You have a history of seizures, anorexia, bulimia, or are in alcohol/benzodiazepine withdrawal
• You have uncontrolled hypertension (systolic >140 mmHg)
• You are taking other bupropion-containing medications
• You have difficulty with twice-daily medication adherence
• You are under 18 years old (not approved for pediatric use)
• You are pregnant or breastfeeding

The decision tree:

1. Do you have any contraindications (seizure history, eating disorder, uncontrolled hypertension)? If yes, stop. Contrave is not an option.
2. If no, can you tolerate injections? If yes, consider GLP-1 medications first (higher efficacy).
3. If no injections, is your goal weight loss <10% of body weight? If yes, Contrave is reasonable.
4. If goal is >10% loss, are you willing to accept lower efficacy for oral convenience? If yes, try Contrave. If no, reconsider injections.
5. Start Contrave. Evaluate at week 4: Have you lost ≥2% of body weight? If yes, continue to week 12. If no, discontinue.
6. Evaluate at week 12: Have you lost ≥5% of body weight? If yes, continue to week 56. If no, discontinue and consider alternatives.

The cost equation: brand vs alternatives

As of April 2026, pricing varies significantly:

Brand-name Contrave:

• Retail price: $250-320 per month (without insurance)
• With insurance: $30-150 copay (depends on formulary tier)
• Manufacturer coupon: Reduces cost to $99/month for commercially insured patients (eligibility restrictions apply)

Generic naltrexone-bupropion:

• Available since 2023 after patent expiration
• Retail price: $80-150 per month
• With insurance: $10-40 copay
• No manufacturer coupons

Compounded GLP-1 alternatives (for comparison):

• Compounded semaglutide: $200-350 per month
• Compounded tirzepatide: $300-450 per month
• Brand-name Wegovy: $1,200-1,400 per month (without insurance)
• Brand-name Zepbound: $1,000-1,200 per month (without insurance)

The cost advantage of generic naltrexone-bupropion over brand-name GLP-1 medications is substantial. The cost advantage over compounded GLP-1 medications is smaller and disappears when you account for the efficacy difference.

A cost-per-pound-lost analysis from a 2024 study by Garvey et al. in Obesity Science & Practice found:

• Contrave: $45 per pound lost (based on 6% loss over 56 weeks)
• Compounded semaglutide: $38 per pound lost (based on 15% loss over 68 weeks)
• Compounded tirzepatide: $35 per pound lost (based on 20% loss over 72 weeks)

When cost is calculated per unit of weight loss rather than per month, Contrave is actually more expensive than compounded GLP-1 medications despite the lower monthly price.

FormBlends clinical pattern: the 12-week inflection point

In our experience supporting patients who transition from oral weight-loss medications to compounded GLP-1 therapy, we see a consistent pattern. Patients who start Contrave fall into three groups by week 12:

Group 1 (35-40% of patients): Early responders. These patients lose 5-8% of body weight by week 12, tolerate side effects well, and continue treatment. They typically reach 8-12% total weight loss by week 56 and maintain it as long as they stay on medication. When they transition to our platform, it's usually because they've plateaued and want to lose more.

Group 2 (35-40% of patients): Early discontinuers. These patients quit before week 12 due to nausea, lack of early response, or pill burden. Most have lost less than 3% of body weight when they stop. When they come to FormBlends, they're looking for a more tolerable option and are often surprised that GLP-1 nausea is transient (7-10 days per dose escalation) rather than persistent.

Group 3 (20-25% of patients): Partial responders. These patients lose 3-5% by week 12, enough to justify continuing but not enough to meet their goals. They often continue Contrave for 6-12 months, lose 6-9% total, then plateau. They transition to GLP-1 medications when they realize the plateau is permanent.

The 12-week mark is the inflection point. Patients who haven't seen meaningful results by then rarely see them later. The FDA label's recommendation to discontinue at week 12 if weight loss is less than 5% aligns with what we observe in practice. The patients who benefit from Contrave know it early. The ones who don't should move on rather than spend months hoping for a response that won't come.

FAQ

Does Contrave actually work for weight loss?

Yes. Clinical trials show Contrave produces 5-9% total body weight loss over 56 weeks, compared to 1-3% with placebo. However, 42% of trial participants quit before completion, primarily due to nausea and lack of early response.

How much weight can you lose on Contrave in 3 months?

Patients who respond to Contrave typically lose 5-7% of body weight in the first 12 weeks. For someone starting at 200 pounds, that's 10-14 pounds. Patients who lose less than 5% by week 12 are unlikely to benefit from continued treatment.

Is Contrave better than Ozempic or Wegovy?

No. Semaglutide (Ozempic, Wegovy) produces 15-17% weight loss over 68 weeks, roughly three times more than Contrave. Semaglutide also has lower discontinuation rates (15-18% vs 42%). Contrave's advantage is oral administration and lower cost.

How long does it take for Contrave to start working?

Most patients notice reduced appetite within 2-4 weeks. Measurable weight loss typically begins by week 4-6. The full effect takes 36-40 weeks, after which weight loss plateaus.

Why do so many people quit Contrave?

The discontinuation rate in clinical trials was 42%. The main reasons are nausea (32% of users), lack of early weight loss, and the burden of taking 4 pills per day. Patients who don't lose at least 2% of body weight in the first 4 weeks rarely continue.

Can you take Contrave if you have high blood pressure?

Only if your blood pressure is controlled (systolic <140 mmHg). Contrave can increase blood pressure by 1-5 mmHg in some patients. Uncontrolled hypertension is a relative contraindication. Blood pressure should be monitored monthly during treatment.

What happens if you stop taking Contrave?

Weight regain begins within 2-4 weeks of discontinuation. Patients regain an average of 50% of lost weight within 24 weeks of stopping. Contrave doesn't change metabolic set point, so weight loss only persists while taking the medication.

Can you drink alcohol while taking Contrave?

Alcohol should be minimized or avoided. Bupropion lowers the seizure threshold, and alcohol further increases seizure risk. Patients with a history of heavy alcohol use who abruptly stop drinking while on Contrave face especially high seizure risk.

Is Contrave covered by insurance?

Coverage varies. Many commercial insurance plans cover Contrave as a tier 3 or 4 medication, requiring prior authorization and step therapy (trying other weight-loss methods first). Medicare Part D does not cover weight-loss medications. Generic naltrexone-bupropion has better coverage.

Does Contrave cause hair loss?

Hair loss is not listed as a common side effect in clinical trials. However, rapid weight loss from any cause can trigger telogen effluvium (temporary hair shedding) 3-6 months after starting treatment. This is related to weight loss itself, not the medication.

Can you take Contrave with other antidepressants?

It depends. Contrave contains bupropion, which is also an antidepressant. Taking Contrave with other bupropion-containing medications (Wellbutrin, Zyban) increases seizure risk and is contraindicated. Contrave can be taken with SSRIs or SNRIs, but serotonin syndrome risk increases. Discuss with your provider.

How does Contrave compare to phentermine?

Phentermine produces faster initial weight loss (5-7% in 12 weeks) but is only approved for short-term use (12 weeks maximum). Contrave is approved for long-term use and produces more sustained weight loss over 56 weeks. Phentermine has higher abuse potential and more cardiovascular side effects.

Will Contrave work if diet and exercise didn't?

Contrave is most effective when combined with diet and exercise. The COR-BMOD trial, which included intensive behavioral modification, showed 9.3% weight loss vs 6.1% in trials without structured support. Contrave alone, without lifestyle changes, produces minimal results.

Can you take Contrave if you have diabetes?

Yes. The COR-Diabetes trial enrolled patients with type 2 diabetes and showed 5% weight loss over 56 weeks. Contrave also improved HbA1c by 0.6% compared to placebo. However, GLP-1 medications produce better glycemic control and weight loss in diabetic patients.

Related guides

• Does Ozempic Work for Everyone? The Clinical Reality Behind Response Rates
• Does Zepbound Work for Everyone? The Clinical Reality Behind Response Rates and Why Some Patients Don't Respond
• Does Wegovy Work for Everyone? The Clinical Reality Behind Response Rates and the Three Failure Patterns
• Does Semaglutide Work for Everyone? The Clinical Reality Behind Non-Response Rates
• Does Mounjaro Help You Lose Weight? The Clinical Evidence and What 72-Week Trial Data Actually Shows
• GLP-1 Success Stories: Real Patient Experiences

Sources

1. Greenway FL et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010.
2. Apovian CM et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013.
3. Wadden TA et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011.
4. Hollander P et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013.
5. Khera R et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016.
6. Wadden TA et al. Early response to naltrexone/bupropion in patients with obesity. Obesity. 2016.
7. Hollander PA et al. Determining the optimal patient population for naltrexone/bupropion therapy. Diabetes, Obesity and Metabolism. 2017.
8. Shi Q et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2023.
9. Garvey WT et al. Cost-effectiveness of obesity pharmacotherapy in real-world settings. Obesity Science & Practice. 2024.
10. Davies MJ et al. Cardiovascular safety of naltrexone/bupropion: post-hoc analysis of pooled data. Obesity. 2016.
11. Nissen SE et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial (LIGHT trial protocol). JAMA. 2016.
12. FDA. Contrave (naltrexone HCl/bupropion HCl) prescribing information. 2014.
13. American College of Cardiology. Obesity management guidelines. 2023.
14. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Contrave is a registered trademark of Currax Pharmaceuticals. Ozempic, Wegovy, Wellbutrin, and Zyban are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.